ACCELERATE Trial
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
ACCELERATE Trial On the Web |
American Roentgen Ray Society Images of ACCELERATE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Evacetrapib has been proven to be a promising CETP inhibitor as it does not show any elevations in blood pressure or aldosterone/cortisol levels[1][2].
- It increases HDL-C and decreases LDL-C levels in a dose dependent manner.[3]
References
- ↑ Nicholls SJ (2012). "Evacetrapib". Current Cardiology Reports. 14 (3): 245–50. doi:10.1007/s11886-012-0252-3. PMID 22362199. Unknown parameter
|month=
ignored (help) - ↑ Cao G, Beyer TP, Zhang Y; et al. (2011). "Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure". Journal of Lipid Research. 52 (12): 2169–76. doi:10.1194/jlr.M018069. PMC 3220285. PMID 21957197. Unknown parameter
|month=
ignored (help) - ↑ Nicholls SJ, Brewer HB, Kastelein JJ; et al. (2011). "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial". JAMA : the Journal of the American Medical Association. 306 (19): 2099–109. doi:10.1001/jama.2011.1649. PMID 22089718. Unknown parameter
|month=
ignored (help)